Introduction
============

With the explosion of high-throughput technologies for measuring various aspects of molecular activity, it has become possible to globally monitor the biochemical activities of cells. Much of the application of these technologies has been in the area of cancer, one major example of which is transcript mRNA microarrays (Schena, 2002). There is now a vast literature on microarray studies done in cancer; a simple PubMed search of the phrase "microarray data, cancer" turns up approximately 2400 entries, 99% of which have been published since 2000.

While there have been many examples of individual molecules, genomic signatures and pathways that have been discovered as being dysregulated in cancer through analyses of gene expression data, a more promising avenue is arising based on consideration of integrating genomic data sources in order to validate previous findings based on gene expression studies and to decipher higher-order modular mechanisms of co-expressed genes enriched in various molecular pathways ([@b12-cin-6-0017]; [@b13-cin-6-0017]).

In cancer, chromosomal aberrations occur frequently. Various types of cytogenetic aberrations, including segmental amplification/deletion and unbalanced translocation events, are a major characteristic of the majority of epithelial tumors. These complex transformations lead to activation of oncogenes and inactivation of tumor suppressor genes. There are many examples of genes that undergo amplifications in cancer, including AKT2 in ovarian cancer, ERRB2 in breast and ovarian cancer, MYCL1 in small cell lung cancer, MYCN in neuroblastoma and EGFR in glioma and non-small cell lung cancer; a comprehensive account of these and other cancer-related genes can be found in [@b3-cin-6-0017]. It has also been shown that many of these changes correlate with clinical factors, such as survival, stage and response to treatment. As an example, for metastatic breast cancer patients with the ERBB2 gene amplification, trastuzumab (Herceptin) is a targeted therapy that is available to achieve a better prognosis.

There are now studies in which microarray data on both an mRNA transcript level as well as a copy number level are being collected. As demonstrated in Virtaneva et al. (2001), a correlation exists between copy number and gene expression in cancer. There are other potential advantages to the integration of copy number and gene expression data. [@b8-cin-6-0017] write that the integration of mRNA transcript and copy number information could lead to the identification of new biomarkers. Similarly, [@b9-cin-6-0017] write that integration of copy number and gene expression data can potentially be used to "understand the effects of gene regulation and transcription in amplification manifestation." With the recently funded Cancer Genome Atlas (<http://cancergenome.nih.gov>), multiple levels of genomic data are being collected on tumor samples. This will be a valuable resource to the cancer research community. A key question then will be how to combine such genomic datasets.

While there are currently few studies in which both transcript mRNA and copy number microarrays are collected on matched samples, we give two examples which have yielded promising results. In a study by [@b4-cin-6-0017], the authors examined Affymetrix SNP array data generated on the celebrated NCI-60 cell line data and then sought to find alterations between tissue-specific cancers. Based on such differences, they then looked for differentially expressed genes in the regions that showed overamplification in the corresponding cell lines. These analyses implicated a new candidate oncogene, MITF. In another study using copy number and gene expression study data from the NCI 60 cell line dataset, [@b1-cin-6-0017] explored the behavior of 64 candidate oncogenes based on correlations between gene expression, copy number and compound activity score. Based on these correlations, they were able to nominate some candidate biomarkers. We term studies of this type as being in the area of cancer "integromics,'' where data measuring different biochemical activities are measured on the same samples. They demonstrate the potential of such datasets to better identify candidate biomarkers in disease progression and prognosis.

In this study, global associations between gene expression and copy number are examined across studies of multiple cancer types. This analysis was motivated for the following reasons. First, knowing the general pattern of correlation structure between the two data types allows us to assess the feasibility of integrative analysis in terms of expected (within-sample) signal-to-noise ratio and variability of the association between copy number and gene expression across samples. Second, it is important to know if the correlation between gene expression and copy number generalizes across different sites of origin. Third, correlation between the two types of data may differ by the nature of samples. In particular, copy number characterization will be distinct depending on whether the study is *in vivo* or *in vitro*. Much of the results reported will be of a descriptive nature. Finally, we will explore higher-order correlations using modern machine learning methodologies ([@b2-cin-6-0017]) as well as bioinformatic methods for segmenting genomic data ([@b10-cin-6-0017]).

Methods
=======

Datasets
--------

Only genomic datasets in which the same samples were profiled on a genomic DNA and transcriptomic basis using two-channel microarray platforms were considered here. Use of the same array (probe) designs on both data types avoids having to perform inter-platform identification mapping of genes.

We searched the Stanford microarray database (<http://genome-www5.stanford.edu/>), Gene Expression Omnibus (<http://www.ncbi.nlm.nih.gov/geo/>) and ArrayExpress (<http://www.ebi.ac.uk/arrayexpress/>) in November 2006 for such complete datasets. Datasets from the following published studies were used: [@b11-cin-6-0017]; [@b6-cin-6-0017]; [@b5-cin-6-0017]; [@b15-cin-6-0017] and [@b7-cin-6-0017]. Here and in the sequel, we will refer to these datasets by the name of the first author. There are three things we note about the datasets. First, all of the datasets except for that from [@b11-cin-6-0017] are from cancer cell lines. Second, the cell lines are from different tissues of origin. This will allow us to observe tissue-specific phenomena. Third, the [@b6-cin-6-0017] and [@b11-cin-6-0017] breast datasets will allow us to assess concordance of copy number/transcript correlations between *in vivo* and *in vitro* systems.

Data Preprocessing
==================

Missing data were imputed using a k-nearest neighbors algorithm with k = 5 ([@b14-cin-6-0017]). Then, a variance filter was applied to the transcript mRNA and copy number micro-array datasets separately. The spots with the lowest 25% variance across all samples were excluded from each dataset. This was done to ensure that the correlations calculated in the study would not be subject to artefacts arising from experimental noise. The final numbers of genes and samples from the available studies are listed in [Table 1](#t1-cin-6-0017){ref-type="table"}.

Results
=======

Univariate correlation study
----------------------------

As an initial analysis, we calculated Pearson correlation between the expression level of every gene with its corresponding copy number expression profile. This is shown in [Table 2](#t2-cin-6-0017){ref-type="table"}.

Comparing the median values for correlation between transcript mRNA and copy number across the five studies is equivalent to the copy number explaining 12%--40% of the variation in gene expression across the five studies. Compared to the 12% figure given by [@b11-cin-6-0017], we find evidence of stronger association in the cell line datasets than in the human tissue. In general, we find weak correlation globally between the transcript mRNA and copy number expression levels. However, on average, we can also say that the correlation distribution appears fairly consistent across studies, with the one exception being the Zhao et al. study, which appears to have a greater amount of variability than the other studies. This is probably due to the small sample size of the study; it has the lowest number of samples among the studies.

We next summarized all possible pairwise univariate correlations between gene expression and copy number. The results are given in [Table 3](#t3-cin-6-0017){ref-type="table"}.The correlation between a gene's expression level and corresponding copy number rarely represents the largest correlation in terms of magnitude in the data-set. [Table 3](#t3-cin-6-0017){ref-type="table"} suggests that there tends to be stronger correlation between transcript levels and copy number if we consider genes from the same chromosome; however, the increase in the proportion of genes with high correlation remains modest. This is a consistent finding with the notion of regulation of gene expression not being a simple relationship. It is also suggestive of a so-called "cis-dosage'' effect of copy number on transcription. We further explored this association using more modern data mining techniques in the next section.

Higher-order correlation studies
--------------------------------

While [Table 1](#t1-cin-6-0017){ref-type="table"} provides a nice summary of the univariate correlations, we also explored higher-order correlation modelling strategies. In particular, we wished to allow for the effects of copy number expression from multiple loci to influence the transcription level of a gene.

The approach we tried was *Least Angle Regression* ("LARS") ([@b2-cin-6-0017]). It involves fitting a linear regression model in which the response variable is gene expression and the copy number expression values from all loci are potential predictors. Since the possible number of predictors is much greater than the number of samples, it is impossible to obtain a unique estimate of the linear regression model. The LARS algorithm allows the user to fit such a model; its estimation procedure involves a sequential and iterative fitting procedure where only m sequential steps are taken. In our case, we take *m* = (number of samples)/2. This implies that a large fraction of the regression coefficients will be estimated to be exactly zero. Below is a description of the LARS procedure:

1.  All coefficients are equal to zero at the beginning, find the predictor most correlated with the response, denote as *x~j1~*.

2.  With *x~j1~* we find *x~j2~* which is most correlated with the current residual vector.

3.  Proceed equiangularly between the two predictors until a third covariate *x~j3~* enters the "most correlated" set.

4.  Proceed equiangularly between *x~j1,~* *x~j21~* and *x~j3~* until the fourth covariate enters, and so on.

After *m* steps, we stop. Thus in the final results of the regression, for each response there are only *m* covariates have non-zero estimated coefficients. Such an approach allows for multiple copy number expression values to influence a given gene's mRNA transcript levels.

Given the results of the LARS analyses for each gene, we can test for a cis-dosage effect. If such an effect exists, then this means that the mRNA expression of one gene is more correlated with the DNA copy number of genes located on the same chromosome than with DNA copy number of genes from different chromosomes. We tested for the presence of a cis-dosage effect using a Wilcoxon test. These results are summarized in Supplementary Table 1.

We draw several conclusions from the table. First, the strength of the cis-dosage effect varies across cancer type. For the purposes of interpreting the table, if we assumed that there was no cis-dosage effect globally, we still would expect approximately one chromosome to show significant evidence of a cis-dosage effect if we are testing at a significance level of 0.05. It is most significant for breast cancer, showing twenty significant chromosomes for the Pollack et al. data and 16 significant chromosomes for the [@b6-cin-6-0017] data. However, for the prostate cancer cell line there only exist 9 significant chromosomes. The correlation patterns for cancer tumor tissue and cell lines from the Pollack and Hyman et al. data, which are both from breast cancer, are similar in that both show strong overall location effect. In conclusion, based on our analysis, the relationship between copy number and expression level is appears to be greater than captured by simple correlation, and the significance of this relationship varies for different cancer types.

The other correlation analysis we performed was to take into account that copy number and gene expression levels might have spatial correlation. This is accommodated through the use of segmentation techniques ([@b10-cin-6-0017]). In particular, we repeated the correlation of analysis in [Table 2](#t2-cin-6-0017){ref-type="table"} by segmenting both the copy number and the gene expression data. Various correlations were calculated and are summarized in [Table 4](#t4-cin-6-0017){ref-type="table"}. This table shows that the single gene copy number-transcript mRNA correlations improve by incorporating segmentation methods into the analysis. This also suggests that incorporating the spatial correlation in gene expression and copy number expression will improve the amount of gene expression variation that is explained by copy number expression.

Discussion
==========

In this study, we have explored the nature of correlation between transcript mRNA and copy number for genes across five cancer profiling studies in which both types of measurements were collected on the same samples. Three findings are notable from this study:

1.  The global nature of correlation between transcript mRNA and copy number is in accordance with what is reported in [@b11-cin-6-0017] and appear to be consistent across studies.

2.  There is solid evidence for a cis-dosage effect of copy number on transcription.

3.  Segmentation of genomic data leads to better correlation, even more than what has been suggested by Pollack et al.

The first result suggests that other phenomena might control and hence be able to explain the variation in gene expression. Examples include histone modifications, mutations in DNA sequence, microRNA molecules and protein activity. This study outlines that there are still many factors that are needed to explain gene expression. With the explosion in new technologies, the effects of other factors on gene expression could potentially be studied. A second and more statistical point is that the weak overall correlation suggests that the approach authors have taken of focusing on specific genes or molecules from "integromic'' analyses of gene expression and copy number data seem to be quite reasonable. If there were stronger correlations between gene expression and copy number, then there would be potential advantage in pooling results from spatially contiguous genes; however, this approach might not lead to any gains in power, given the nature of correlation that we are finding here. Of course, if there are sample-specific artefacts, then using the correlation coefficient across samples might lead to erroneous conclusions.

One major limitation of our study is that we are not considering clinically heterogeneous samples at all, i.e. we treat each study as having samples coming from one population. With samples from the Cancer Genome Atlas, there will be linked clinical information to the genomic data. It might be the case that the nature of correlation will change depending on certain clinical parameters. This was the approach implicitly utilized by [@b1-cin-6-0017] and is potentially powerful for finding new biomarkers. How to incorporate clinical information into the analysis is an open area of research and is currently under investigation.

Much of the results we have reported have been based on descriptive measures. A challenging issue is how to perform statistical inference. While permutation procedures are quite popular, it is not clear what should be permuted. In addition, if one wishes to incorporate spatial dependence, then clearly a model-based approach is needed.

Finally, this should be viewed as an initial study in the area. With the possibility of larger-sized datasets emerging in the future, the nature of copy number and gene expression will be more reliably assessed. By finding consistent patterns across the individual datasets, this provides some strength of evidence to our study.

Supplementary Material
======================

**Table S1.** Results of the LARS analyses to find cis-dosage effects of copy number on gene expression. The results are grouped by first study author. Chrm refers to chromosome. Average number of non-zero betas denotes the average number of copy number expression measurements from the same chromosome found to have a non-zero effect on gene expression for all genes on the chromosome. Expected number of non-zero betas denotes the average number of non-zero betas under the null hypothesis of no-cis dosage effect. P-value is based on the Wilcoxon rank-sum test.
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###### 

Description of datasets used in the analysis. Dataset column refers to first author on publication containing data.

  Dataset      Organ site   In vivo/in vitro   Number of genes   Number of samples
  ------------ ------------ ------------------ ----------------- -------------------
  Pollack      Breast       In vivo            4841              36
  Hyman        Breast       In vitro           6823              14
  Heidenblad   Pancreas     In vitro           8879              16
  Zhao         Prostate     In vitro           14824             8
  Kim          Lung         In vitro           21066             22

###### 

Summary statistics for pair wise correlation between copy number and expression.

  Dataset      Min     1st Quantile   Median   Mean   3rd Quantile   Max    SD
  ------------ ------- -------------- -------- ------ -------------- ------ ------
  Pollack      −0.49   −0.02          0.11     0.12   0.26           0.90   0.22
  Hyman        −0.83   −0.07          0.14     0.15   0.36           0.99   0.31
  Heidenblad   −0.79   −0.04          0.16     0.15   0.34           0.92   0.28
  Zhao         −0.95   −0.14          0.19     0.16   0.48           0.99   0.41
  Kim          −0.79   0.02           0.22     0.20   0.39           0.94   0.27

**Notes:** Min refers to minimum; Max refers to maximum. SD is standard deviation.

###### 

Summary of univariate correlation results across five studies.

  Dataset      Number of genes   \# genes most correlated with themselves   \# genes most correlated with genes from the same chromosome
  ------------ ----------------- ------------------------------------------ --------------------------------------------------------------
  Pollack      4841              42 (0.90%)                                 619 (13.21%)
  Hyman        6823              28 (0.41%)                                 648 (9.50%)
  Heidenblad   8879              8 (0.09%)                                  713 (8.03)
  Zhao         14284             3 (0.02%)                                  853 (6.09%)
  Kim          21066             79 (0.5%)                                  2344 (14.0%)

**Notes:** In this table, the second column refers to the number of genes in which the largest correlation in magnitude with copy number is that from the same gene (i.e. the same spot on the microarray). The third column refers to the number of genes whose largest correlation between expression and copy number was with a spot that mapped to a gene on the same chromosome.

###### 

Correlations across five datasets taking segmentation into account.

  ---------------------- -------- --------- --------- --------- ---------- -------- ---------
  **Hyman**              **0%**   **25%**   **50%**   **75%**   **100%**   **SD**   **MAD**
  Both Unsegmented       −0.859   −0.057    0.159     0.373     0.956      0.303    0.246
  Expression Segmented   −0.805   −0.025    0.211     0.432     0.974      0.317    0.259
  Copynumber Segmented   −0.902   −0.022    0.219     0.453     0.969      0.324    0.267
  Both Segmented         −0.734   0.259     0.471     0.652     0.976      0.281    0.224
  **Heidenblad**         **0%**   **25%**   **50%**   **75%**   **100%**   **SD**   **MAD**
  Both Unsegmented       −0.777   −0.051    0.147     0.34      0.949      0.276    0.224
  Expression Segmented   −0.746   0.069     0.268     0.463     0.948      0.285    0.229
  Copynumber Segmented   −0.804   −0.008    0.196     0.395     0.952      0.288    0.234
  Both Segmented         −0.691   0.247     0.464     0.645     0.975      0.288    0.231
  **Pollack**            **0%**   **25%**   **50%**   **75%**   **100%**   **SD**   **MAD**
  Both Unsegmented       −0.547   −0.028    0.106     0.248     0.898      0.208    0.165
  Expression Segmented   −0.607   0.082     0.241     0.399     0.947      0.226    0.183
  Copynumber Segmented   −0.54    0.005     0.166     0.331     0.914      0.231    0.186
  Both Segmented         −0.396   0.327     0.479     0.62      0.971      0.214    0.172
  **Zhao**               **0%**   **25%**   **50%**   **75%**   **100%**   **SD**   **MAD**
  Both Unsegmented       −0.946   −0.127    0.196     0.488     0.989      0.406    0.338
  Expression Segmented   −0.939   0.085     0.42      0.675     0.99       0.401    0.331
  Copynumber Segmented   −0.968   −0.115    0.227     0.525     0.99       0.418    0.348
  Both Segmented         −0.923   0.309     0.623     0.819     0.997      0.383    0.304
  **Kim**                **0%**   **25%**   **50%**   **75%**   **100%**   **SD**   **MAD**
  Both Unsegmented       −0.803   0.051     0.241     0.42      0.972      0.263    0.214
  Expression Segmented   −0.726   0.124     0.328     0.522     0.932      0.279    0.228
  Copynumber Segmented   −0.722   0.077     0.287     0.479     0.957      0.278    0.228
  Both Segmented         −0.644   0.275     0.482     0.675     0.924      0.282    0.228
  ---------------------- -------- --------- --------- --------- ---------- -------- ---------

**Notes:** SD represents standard deviation; MAD represents mean absolute deviation. Both Unsegmented refers to correlation coefficients between gene expression and copy number based on the raw expression number value, after taking the preprocessing steps described in the paper. Expression Segmented refers to running the algorithm of [@b10-cin-6-0017] on the gene expression data on individual samples and to then calculate the correlation coefficients between gene expression and copy number expression. Copynumber Segmented refers to running the algorithm of [@b10-cin-6-0017] on the copy number expression data on individual samples and to then calculate the correlation coefficients between gene expression and copy number expression. Both Segmented refers to running the algorithm of [@b10-cin-6-0017] on the copy number and gene expression data on individual samples and to then calculate the correlation coefficients between gene expression and copy number expression.
